Abstract. Depression is a multifaceted psychiatric condition affecting more than 280 million individuals globally across diverse age brackets, constituting 12.3% of the worldwide disease burden. Among the varied manifestations, Major Depressive Disorder (MDD) stands out as a prevalent and severe form of psychopathology. The origins of depression, while not fully elucidated, are generally attributed to the intricate interplay of environmental, societal, and individual factors. Recent preclinical and clinical investigations have posited a potential association between dysbiosis, characterized by alterations in gut microbiota composition and function, and the initiation and progression of depression. Nevertheless, the precise mechanisms remain unclear, and the gut microbiota has not been a primary focal point in depression therapeutic strategies. This review outlines conceivable mechanisms linking dysbiosis in the gut microbiota to the development of depression, elucidating the intricate relationship between dysbiosis and depressive conditions. Additionally, it explores the interplay between pharmacological interventions and the gut microbiota in the context of antidepressant therapy. Simultaneously, the article investigates the potential and merits of probiotics and prebiotics as tools to modulate gut microbiota and maintain a stable gut microenvironment, positioning them as innovative agents in antidepressant therapy. This perspective introduces a novel trajectory for future research and clinical approaches in depression, underscoring the significance of preserving gut microbiota equilibrium as a promising avenue for intervention.
Read full abstract